BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2014 4:56:00 PM | Browse: 1110 | Download: 1485
 |
Received |
|
2013-07-20 09:18 |
 |
Peer-Review Started |
|
2013-07-22 19:22 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2013-08-16 19:57 |
 |
Revised |
|
2013-09-12 19:57 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2013-10-11 14:57 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2013-10-12 00:37 |
 |
Articles in Press |
|
|
 |
Edit the Manuscript by Language Editor |
|
2013-10-18 17:18 |
 |
Typeset the Manuscript |
|
2013-10-29 16:35 |
 |
Publish the Manuscript Online |
|
2013-12-03 15:44 |
| Category |
Oncology |
| Manuscript Type |
Autobiography |
| Article Title |
Long-term survival of more than 3 years among patients with advanced non-small cell lung cancer treated with chemotherapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Rieko Kaira, Kyoichi Kaira, Takehito Shukuya, Hirotsugu Kenmotsu, Akira Ono, Haruyasu Murakami, Asuka Tsuya, Yukiko Nakamura, Tateaki Naito, Masahiro Endo, Nobuyuki Yamamoto and Toshiaki Takahashi |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Kyoichi Kaira, MD, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. kkaira1970@yahoo.co.jp |
| Key Words |
Non-small cell lung cancer; Long-term survivor; Chemotherapy; Performance status; Epidermal growth factor receptor-tyrosine kinase inhibitors |
| Core Tip |
The aim of this study is to evaluate the prognostic factors of long-term survival of more than 3 years in advanced non-small cell lung cancer. Female sex, good performance status (PS), non-smoker and adenocarcinoma were significantly associated with long-term survivors of more than 3 years and most patients received epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) at any line treatment. PS of 0 was an independent prognostic factor for predicting favorable prognosis in the long-term survivors of more than 3 years. PS of 0, adenocarcinoma and EGFR-TKI therapy play an important role in the long-term survivors. |
| Publish Date |
2013-12-03 15:44 |
| Citation |
Kaira R, Kaira K, Shukuya T, Kenmotsu H, Ono A, Murakami H, Tsuya A, Nakamura Y, Naito T, Endo M, Yamamoto N, Takahashi T. Long-term survival of more than 3 years among patients with advanced non-small cell lung cancer treated with chemotherapy. World J Respirol 2013; 3(3): 110-115 |
| URL |
http://www.wjgnet.com/2218-6255/full/v3/i3/110.htm |
| DOI |
http://dx.doi.org/10.5320/wjr.v3.i3.110 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.